Pneumococcal Polyvalent Vaccine
Nodal Marginal Zone B-cell Lymphoma
Mayo ClinicvaccineEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
38 Active assets in the Nodal Marginal Zone B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide SWOG Cancer Research Network | Phase 2 | BB |
Fludarabine UNC Lineberger Comprehensive Cancer Center | Phase 2 | BB |
ETOPOSIDE University of California, Davis | Phase 2 | BB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Pneumococcal Polyvalent Vaccine is also rated in:
pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →